Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5556880 | 0.80 | DAO (0.44) | DAOGSK3BSLC6A2SLC6A4 | |
| SCHEMBL5555505 | 0.79 | DAO (0.49) | DAOGSK3BSLC6A2SLC6A4CYP2D6 | |
| SCHEMBL5555871 | 0.78 | ALAD (0.31) | — | |
| SCHEMBL5555876 | 0.74 | GSK3B (0.41) | GSK3B | |
| SCHEMBL5555276 | 0.74 | DAO (0.46) | DAO | |
| SCHEMBL5555874 | 0.73 | MAPT (0.38) | GSK3B | |
| SCHEMBL5560715 | 0.73 | — | — | |
| SCHEMBL4039600 | 0.67 | GRM4 (0.37) | SLC6A4CYP2D6 | |
| SCHEMBL4039603 | 0.67 | GRM4 (0.37) | SLC6A4CYP2D6 | |
| SCHEMBL27534655 | 0.66 | GSK3B (0.69) | DAOGSK3BSLC6A2SLC6A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1565451-B1 | HALOTHIENOYL-CYCLOPROPANE-1-CARBOXYLIC ACID DERIVATIVES | NEWRON PHARM SPA (IT) | 2007-05-09 | — | — | EP | disclosed |
| US-20060116329-A1 | Halothenoyl-cyclopropane-1-carboxylic acid derivatives | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2006-06-01 | — | — | US | disclosed |
| EP-1424333-A1 | Halothenoyl-cyclopropane-1-carboxylic acid derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2004-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116329-A1 | Halothenoyl-cyclopropane-1-carboxylic acid derivatives | KMO, HAO1, DAO | DAO 3/4885GSK3B 3543/4885SLC6A2 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.